Taysha Gene Therapies Inc. (TSHA) News
Filter TSHA News Items
TSHA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TSHA News Highlights
- TSHA's 30 day story count now stands at 2.
- Over the past 20 days, the trend for TSHA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- GENE, AGE and LOAN are the most mentioned tickers in articles about TSHA.
Latest TSHA News From Around the Web
Below are the latest news stories about TAYSHA GENE THERAPIES INC that investors may wish to consider to help them evaluate TSHA as an investment opportunity.
Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene TherapiesTrinity Capital Inc. (NASDAQ: TRIN) ("Trinity"), a leading provider of diversified financial solutions to growth-stage companies, today announced the commitment of $40 million in term loans to Taysha Gene Therapies, Inc. (NASDAQ: TSHA) ("Taysha"), a clinical-stage gene therapy company, pursuant to a Loan and Security Agreement dated November 13, 2023, by and among Taysha, the lenders party thereto from time to time (the "Lenders"), and Trinity, as administrative agent and collateral agent for th |
Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome PatientsHealth Canada authorized the Company’s protocol amendment that expands eligibility to include patients aged 12 and older with stage four Rett syndrome in the REVEAL Phase 1/2 adult trial in Canada Protocol amendment broadens TSHA-102 treatment potential to both adolescent and adult patients with Rett syndrome Dosing of the third patient in the REVEAL Phase 1/2 adult trial (age 12+ protocol) and completion of cohort one (low dose) expected in the fourth quarter of 2023/first quarter of 2024 DALLA |
Insider Buying: Taysha Gene Therapies Board Observer Bought US$163k Of SharesInvestors who take an interest in Taysha Gene Therapies, Inc. ( NASDAQ:TSHA ) should definitely note that the Board... |
Party Time: Brokers Just Made Major Increases To Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Earnings ForecastsCelebrations may be in order for Taysha Gene Therapies, Inc. ( NASDAQ:TSHA ) shareholders, with the analysts delivering... |
Analysts Are Upgrading Taysha Gene Therapies, Inc. (NASDAQ:TSHA) After Its Latest ResultsIt's been a good week for Taysha Gene Therapies, Inc. ( NASDAQ:TSHA ) shareholders, because the company has just... |
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2023 Earnings Call TranscriptTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2023 Earnings Call Transcript November 14, 2023 Taysha Gene Therapies, Inc. reports earnings inline with expectations. Reported EPS is $-0.13 EPS, expectations were $-0.13. Operator: Good afternoon and welcome to the Taysha Gene Therapies Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. […] |
Q3 2023 Taysha Gene Therapies Inc Earnings CallQ3 2023 Taysha Gene Therapies Inc Earnings Call |
Taysha Gene Therapies Inc (TSHA) Reports Q3 2023 Financial Results and Clinical ProgressKey Clinical Advances and Financial Position Strengthened; Cash Runway Extended into 2026 |
Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical UpdatesREVEAL Phase 1/2 REVEAL Phase 1/2 Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated with no treatment-emergent SAEs as of 20-week assessment with sustained improvement across key efficacy measures and new improvement in R-MBA, PGI-I and hand function, a hallmark characteristic of Rett syndrome at week 12 Data from second adult patient showed TSHA-102 was well-tolerated with no treatment-emergent SAEs as of six-week assessment with improvement across key e |
Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14DALLAS, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2023, and host a corporate update conference call and webcast on Tuesday, November 14, 2023, at 4:30 PM Eastern Time. Conference Cal |